SCYNEXIS, Inc. (NASDAQ:SCYX) has been given an average rating of “Buy” by the eight research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $8.55.

SCYX has been the topic of a number of research reports. Zacks Investment Research upgraded SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Wednesday, August 2nd. Roth Capital set a $9.00 price objective on SCYNEXIS and gave the company a “buy” rating in a research note on Monday, August 7th. HC Wainwright set a $14.00 price objective on SCYNEXIS and gave the company a “buy” rating in a research note on Wednesday, August 16th. Guggenheim initiated coverage on SCYNEXIS in a research note on Tuesday. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, ValuEngine cut SCYNEXIS from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd.

Shares of SCYNEXIS (SCYX) traded down 1.59% during trading on Thursday, hitting $1.86. 196,745 shares of the stock traded hands. The stock’s market cap is $49.70 million. The stock has a 50 day moving average price of $2.20 and a 200-day moving average price of $1.99. SCYNEXIS has a 1-year low of $1.52 and a 1-year high of $4.04.

WARNING: “SCYNEXIS, Inc. (SCYX) Receives Average Recommendation of “Buy” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/26/scynexis-inc-scyx-receives-average-recommendation-of-buy-from-brokerages-2.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. National Asset Management Inc. bought a new stake in shares of SCYNEXIS during the second quarter valued at about $551,000. Federated Investors Inc. PA increased its position in shares of SCYNEXIS by 23.5% during the second quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock valued at $7,533,000 after buying an additional 800,040 shares during the period. Bank of New York Mellon Corp increased its position in shares of SCYNEXIS by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock valued at $103,000 after buying an additional 512 shares during the period. KCG Holdings Inc. bought a new stake in shares of SCYNEXIS during the first quarter valued at about $416,000. Finally, DAFNA Capital Management LLC increased its position in shares of SCYNEXIS by 32.7% during the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock valued at $907,000 after buying an additional 125,000 shares during the period. Hedge funds and other institutional investors own 36.76% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.